Drug intelligence / Profile preview

XS003

Development stage: Phase 1
Lead developer: Xspray Pharma
Modality: Small Molecules
Administration: Oral

Overview

XS003 is an amorphous, non-crystalline formulation of nilotinib developed using Xspray Pharma's proprietary HyNap™ technology. It is designed to overcome therapeutic limitations of the currently available crystalline formulation of nilotinib (TASIGNA®). XS003 has demonstrated bioavailability matching TASIGNA® at more than a 50% reduced dose and is specifically designed to reduce food interactions that complicate prescribing and adherence to existing nilotinib therapies.

Targets

ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on XS003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XS003.

Explore the full profile